Nektar Therapeutics (NASDAQ:NKTR) Expected to Earn FY2023 Earnings of ($0.85) Per Share

Nektar Therapeutics (NASDAQ:NKTR – Free Report) – Equities research analysts at Zacks Research lowered their FY2023 earnings per share estimates for shares of Nektar Therapeutics in a research note issued to investors on Tuesday, January 23rd. Zacks Research analyst K. Das now expects that the biopharmaceutical company will post earnings per share of ($0.85) for […]

Related Keywords

Monaco ,United States , ,Acadian Asset Management ,Nektar Therapeutics Company Profile ,Blackrock Inc ,Jpmorgan Chase Co ,Zacks Research ,Nektar Therapeutics ,Free Report ,Nektar Therapeutic ,Get Free Report ,Track Capital ,Asset Management ,Nektar Therapeutics Daily ,Nasdaq Nktr ,Nktr ,Medical ,64026810 ,Earnings Estimates ,